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Abstract  1 
Objectives: To determine the impact of excluding patient global assessment (PGA) from the 2 
ACR/EULAR Boolean remission criteria, upon prediction of radiographic and functional 3 
outcome of RA. 4 
Methods: Meta-analyses using individual patient data from RCTs testing the efficacy of 5 
biological agents on radiographic and functional outcomes at ≥2 years. Remission states were 6 
defined by 4 variants of the ACR/EULAR Boolean definition: (i) tender and swollen 28-joint 7 
counts (TJC28/SJC28), C-reactive protein (CRP, mg/dl), and PGA (0-10=worst) all≤1 (4V-8 
remission), (ii) the same, except PGA>1 (4V-near-remission), (iii) 3V-remission (i and ii 9 
combined; similar to 4V, but without PGA), and (iv) non-remission (TJC28>1 and/or SJC28>1 10 
and/or CRP>1). The most stringent class achieved at 6 or 12 months was considered. Good 11 
radiographic (GRO) and functional outcome (GFO) were defined as no worsening (i.e. change 12 
in modified Total Sharp score ≤0.5 units and ≤0.0 HAQ-DI points, respectively, during the 13 
second year. The pooled probabilities of GRO and GFO for the different definitions of remission 14 
were estimated and compared. 15 
Results: Individual patient data (n=5,792) from eleven trials were analysed. 4V-remission was 16 
achieved by 23% of patients and 4V-near-remission by 19%. The probability of GRO in the 4V-17 
near-remission group was numerically, but non-significantly, lower than that in the 4V-18 
remission (78 vs 81%) and significantly higher than that for non-remission (72%; 19 
difference=6%, 95%CI:2-10%). Applying 3V-remission could have prevented therapy 20 
escalation in 19% of all participants, at the cost of an additional 6.1%, 4.0%, and 0.7% of 21 
patients having ΔmTSS>0.0, >0.5, and >5 units over 2 years, respectively. The probability of 22 
GFO (assessed in 8 trials) in 4V-near-remission (67%, 95%CI:63-71%) was significantly lower 23 
than in 4V-remission (78%, 74-81%) and similar to non-remission (69%, 66-72%). 24 
Conclusion: 4V-near-remission and 3V-remission have similar validity as the original 4V-25 
remission definition in predicting GRO, despite expected worse prediction of GFO, while 26 
potentially reducing the risk of overtreatment. This supports further exploration of 3V-remission 27 
as the target for immunosuppressive therapy complemented by patient-oriented targets.  28 
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KEY MESSAGES 1 
What is already known about this subject? 2 
• Few previous studies compared the prediction of good structural and functional 3 
outcomes between patients who fulfilled all four criteria of the current ACR/EULAR 4 
Boolean-based definition of remission ("4V-remission") versus those who attained only 5 
three ("3V-remission"), i.e. excluding patient global assessment (PGA). No significant 6 
differences were found but the two groups of patients evaluated significantly overlap.  7 
 8 
What does this study add? 9 
• This was the first study comparing these outcomes between patients achieving 4V-10 
remission (23%) and those missing this status due solely to PGA above 1/10 (4V-near-11 
remission) (19%). It is based on individual patient data meta-analysis of 11 recent 12 
clinical trials in RA (5,792 patients). 13 
• The rate of good radiographic outcome (≤0.5 units progression over the second year) 14 
was numerically higher in patients in 4V-remission (81%; 95%CI 74 to 87%) than in 15 
those in 4V-near-remission (78%; 95%CI: 69 to 86%), but the difference is not 16 
statistically significant.  17 
• In this population, if a ‘treat-to-remission’ strategy had been applied, the 3V-remission 18 
definition would have prevented therapy escalation in 19% of all patients, at the cost of 19 
an additional 6.1%, 4.0%, and 0.7% of patients having ΔmTSS>0.0, >0.5 and >5 units 20 
over 2 years, respectively.   21 
 22 
How might this impact on clinical practice or future developments? 23 
• These results suggest that the use of 3V-remission as the target for immunosuppressive 24 
therapy, together with a separate assessment of disease impact upon patient’s lives, a 25 
dual target approach, deserves further consideration and research.   26 
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INTRODUCTION 1 
Disease remission has become the guiding target in the management of rheumatoid arthritis 2 
(RA), as it conveys the best possible outcomes.[1] Current treatment recommendations advise 3 
that remission (or at least low disease activity) should be attained as soon and as consistently 4 
as possible, and changes in treatment should be considered when this does not happen.[2, 3] 5 
The most influential and authoritative definition of remission was published in 2011 under the 6 
auspices of the American College of Rheumatology (ACR), the European League Against 7 
Rheumatology (EULAR) and the Outcome Measures in Rheumatology (OMERACT) groups.[4] 8 
A Boolean-based definition was endorsed: and requires that scores of tender and swollen 28-9 
joint counts (TJC28 and SJC28), C-Reactive Protein (CRP, in mg/dl), and patient global 10 
assessment of disease activity (PGA, 0–10 scale) are all ≤1.[4] 11 
The inclusion of PGA in the definitions of remission in RA was justified because it added 12 
predictive value for later good radiographic and functional outcomes, while conveying the 13 
much-needed patient's perspective.[4]   14 
Despite this, the inclusion of PGA remains controversial.[5-9] Using the definitions above, 15 
studies in different clinical practice cohorts,[10-15] have reported that as many as 10%[13] to 16 
38%[14] of all patients with RA, do not reach remission solely due to a PGA score >1, a state 17 
that has become designated as "4V-near-remission".[14, 16] Moreover, it has been 18 
demonstrated that PGA bears little relationship with markers of the disease process, which 19 
drives structural damage, rather reflecting pain, fatigue and function.[9, 17, 18] This is 20 
especially evident when analyses are restricted to the lower levels of disease activity, in the 21 
range where the definition of remission has a decisive impact on whether to maintain or to 22 
escalate immunosuppressive treatment. According to this perspective, patients in 4V-near-23 
remission would not benefit from additional immunosuppression, as this cannot be expected 24 
to improve their condition or foster remission,[9, 17] and are exposed by current 25 
recommendations to the risk of overtreatment and unjustified side-effects.[19] 26 
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These observations have led to the suggestion that the patients' interest would be better 1 
served by the adoption of two separate complementary targets: the first focused on remission 2 
of the inflammatory process, guided by an instrument without PGA; the second focused only 3 
on patient-reported impact measures.[9, 16, 20] However, this proposal would not be 4 
sustainable if, as suggested in the original ACR/EULAR/OMEARCT paper, removing PGA 5 
from the Boolean-based remission significantly diminishes its ability to predict good 6 
radiographic and functional outcome.[4]  A systematic literature review (SLR) indicated that, 7 
among the individual components included in the definitions of remission, only swollen joints 8 
and acute phase reactants are associated with radiographic progression.[21] Two other 9 
studies, using data from a clinical cohort[13] and from clinical trials,[22] compared the 10 
prediction of good radiographic outcome by "4V-remission" versus "3V-remission" (without 11 
PGA) achieved in RA patients: no significant differences were observed, but the two groups 12 
were not mutually exclusive. No study has ever compared the radiographic outcomes between 13 
the 4V-remission and 4V-near-remission groups.  14 
The primary aim of this study was to compare 4V-near-remission and 4V-remission regarding 15 
their association with radiographic damage progression. Secondarily, we aimed to explore the 16 
impact of using 3V- instead of 4V-remission in patients with RA, both in terms of prevalence of 17 
remission and association with structural damage progression and functional impairment.  18 
 19 
METHODS 20 
Design and study selection 21 
This was an individual patient data meta-analysis of published randomized controlled trials 22 
(RCTs) selected through a systematic literature review. The study protocol was registered in 23 
PROSPERO with the number CRD42017057099[23] and published elsewhere.[24] 24 
RCTs were included if they tested the efficacy of biological disease-modifying antirheumatic 25 
drugs (bDMARDs) on ≥2-year radiographic outcomes, in patients fulfilling the 1987 ACR or the 26 
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2010 ACR-EULAR criteria for RA.[25, 26] Information on the processes of identifying and 1 
selecting studies, as well collecting data are reported in the protocol.[24] 2 
 3 
Risk of bias assessment of individual studies 4 
Studies selected for retrieval were assessed by two independent reviewers (RF and MN) for 5 
methodological validity prior to inclusion in this review, using the “Risk of Bias 2” tool.[27] Any 6 
disagreements between the reviewers were resolved through discussion, or with a third 7 
reviewer (JAPS). The full protocols of the studies were consulted, and their authors contacted 8 
to request missing or additional data for clarification, where required. 9 
 10 
Specification of outcomes 11 
Primary outcome 12 
The primary outcome of this study was the percentage of individuals with a good radiographic 13 
outcome (GRO) during the second year of the trial (i.e. between month 12 and month 24), 14 
defined as: a change (Δ) ≤0.5 units in the van der Heijde modified-total Sharp score 15 
(mTSS).[28] 16 
This ≤0.5 cut-off is preferred[29-31] over the one used in the ACR/EULAR pivotal publication 17 
(≤0 cut-off), because 0.5 is the optimal cut-off if the average of two readers is used,[32] as it 18 
allows to the very minimum difference of 1 unit out of 448 between the two readers. 19 
 20 
Secondary outcomes 21 
Two secondary endpoint cut-offs were used to define good radiographic outcome during the 22 
second year of the trial: 23 
i. ΔmTSS≤5 units, a higher, frequently used rate (sometimes referred to as clinically non-24 
relevant radiographic progression);  25 
ii. ΔmTSS≤0 units, to allow comparisons with the results obtained in the ACR/EULAR 26 
study.[4]   27 
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Also as secondary outcome we studied the percentage of individuals with a good functional 1 
outcome (GFO) during the second year of the trial (i.e. between month 12 and month 24), 2 
defined as no worsening i.e. a change (Δ) ≤0.0 units in the Health Assessment Questionnaire 3 
– Disability Index (HAQ-DI). This definition has been preferred over the one used in the 4 
ACR/EULAR pivotal publication (Δ HAQ≤0.0 AND HAQ≤0.5 at both time points), because this 5 
is believed to be too strict, representing a better outcome even than expected for general 6 
population.[4, 33] Despite this consideration, this definition of GFO was also tested to allow 7 
comparison with the original ACR/EULAR paper. 8 
 9 
Comparisons: mutually and non-mutually exclusive definitions of remission  10 
Analyses were based on different definitions of remission states, assessed at two time points, 11 
6 months and 12 months, following the methodology adopted by the ACR/EULAR 12 
committee,[4]  as follows: 13 
a) ACR/EULAR Boolean-based remission,[4] also designated in this study as "4V-14 
Remission" (i.e., TJC28≤1, SJC28≤1, CRP≤1 mg/dl, and PGA≤1/10)  15 
b) "4V-near-remission",[11, 14] defined as TJC28≤1, SJC28≤1, CRP≤1 mg/dl, and 16 
PGA>1.  17 
c) "Non-remission" defined as TJC28>1 and/or SJC28>1 and/or CRP>1 mg/dl, 18 
irrespective of PGA value. 19 
The above three definitions are mutually exclusive, i.e. each patient was categorized in one 20 
group only.  21 
d) "3V-remission" defined as TJC28≤1, SJC28≤1, and CRP≤1 mg/dl. This is a combination 22 
of 4V-remission and 4V-near-remission - patients classified in 4V-remission also meet 23 
the 3V-remission criteria (Figure 1). 24 
All definitions of remission were considered fulfilled if they were achieved at 6 OR 12 months’ 25 
follow-up and patients were classified according to the most stringent definition they satisfied 26 
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(for instance, if a patient was in 4V-near-remission at 6 months and in 4V-remission at 12 1 
months, he/she was classified as in 4V-remission). 2 
 3 
Data analysis and synthesis 4 
Data analysis  5 
All "primary" analyses were performed with SAS software (v.9.3), within the online secure 6 
platforms. For each trial we determined the number of patients with GRO in each definition 7 
group (4V-remission, 4V-near-remission, 3V remission and non-remission). The rates of true 8 
positive (TP) i.e. remission and GRO, true negative (TN) i.e. non-remission and not-GRO, false 9 
negative (FN) i.e. non-remission and GRO, and false positive (FP) i.e. remission and not-GRO 10 
cases were also determined for all definitions. The percentage of patients with accurate 11 
prediction of having and not having GRO were also determined (sum of TP and TN) for the 12 
4V- and 3V-remission. Missing data was not substituted. Similar analyses were performed for 13 
the secondary outcomes. 14 
 15 
Meta-analysis  16 
Frequency of remission status and outcomes 17 
The frequency/proportion of each remission state observed in each of the trials were meta-18 
analysed, irrespective of the treatment arm. The same procedure was used to determine the 19 
pooled prevalence of GRO and GFO according to remission status.   20 
Primary analysis: likelihood of achieving GRO for 4V-near-remission compared to 4V-21 
remission and to non-remission 22 
From our hypothesis that PGA might lead to false negative rating of remission when using the 23 
4V-remission definition, we aimed to analyse the value of 3V-remission definition, excluding 24 
PGA. Direct comparison of 4V-remission and 3V-remission however is not possible, given the 25 
overlap between the two states (see Figure 1). Therefore, for each trial we determined the 26 
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differences in the proportion/chance (∆ proportion) of GRO (∆mTSS≤0.5) between 4V-near-1 
remission and 4V-remission, mutually exclusive states, and then pooled these differences with 2 
the random effect model to obtain an overall estimate of the difference (with 95%CI). We also 3 
compared this between 4V-near-remission and non-remission states. The Risk Ration or 4 
Relative Risk (RR, 95%CI) for GRO between these groups were also calculated.  5 
Secondary analyses: The likelihood of achieving each of the secondary outcomes for 4V-near-6 
remission compared to 4V-remission and to non-remission was assessed using similar 7 
methods for the different definitions. 8 
 9 
Sensitivity analyses 10 
Different sensitivity analyses were performed regarding radiographic progression. The first was 11 
to explore the likelihood of GRO between remission states after excluding the seemingly outlier 12 
trials. 13 
The second was a multivariate analysis. Multivariate logistic regressions were performed in 14 
each trial to explain GRO (dependent variable) using the mutually exclusive remission states 15 
as independent variables, adjusted for important covariates at baseline: gender, age, disease 16 
duration (except for three trials due to >50% of missing data in this covariate), rheumatoid 17 
factor status, level of radiographic damage, and treatment arm. The OR obtained in each trial 18 
and its 95%CI and standard error were meta-analysed to obtain the pooled OR of GRO 19 
comparing different mutually-exclusive remission states. However, we hypothesise that this 20 
covariate adjustment may constitute an overcorrection, because patients in remission are 21 
‘naturally’ different from patients not in remission regarding these prognostic factors. For this 22 
reason, these sensitivity analyses are presented cautiously and only in supplementary 23 
material. 24 
The third was to clarify the value of PGA as a predictor of radiographic damage progression, 25 
selecting only the patients in 4V-near-remission (in 8 of the 11 trials, 796 patients, due to 26 
restrictions in accessing the data). We used Poisson regression models with 2y mTSS as 27 
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dependent variable and PGA as independent variable. To assess the specific, independent 1 
impact of PGA, we corrected for SJC28, TJC28 and CRP, determined as the mean of the 2 
observation at 6 and 12 months, by also introducing them as independent variables, together 3 
with baseline mTSS. To allow the combined analysis the different variables, we standardized 4 
their values using z-scores. A meta-analysis was then performed to obtain pooled rate ratios 5 
(RR with 95% CI) per variable. 6 
The last was to explore the proportion of patients in 3v-remission (8 trials; 1,937 patients) who 7 
have radiographic damage progression ≥0.5 and those who have radiographic progression ≥5 8 
during year 2, according to PGA score ≤1 versus >1 at 6 and 12 months). 9 
 10 
Likelihood of reaching good radiographic and functional outcomes with 4V-remission 11 
compared to 3V-remission 12 
If the null hypothesis of this study (the chance of GRO in 4V-near-remission group are similar 13 
to the 4V-remission group) is not rejected, the current 4V-remission and the proposed 3V-14 
remission can be compared in terms of their positive (LR+) and negative likelihood ratios (LR-15 
) of GRO per remission group. The TP, TN, FN, and FP values were used to synthesize these 16 
measures. Similar procedures were performed regarding GFO. 17 
All meta-analyses were performed with the OpenMeta[Analyst] software,[34] using the 18 
DerSimonian-Laird random-effect method[35] and the Arcsine transformed proportion.[36] The 19 
STATA software (v.14) was used only to determine OR adjusted to covariates (sensitivity 20 
analyses). The I2 of Higgins and Thompson was calculated to quantify heterogeneity.[37] 21 
 22 
 23 
RESULTS 24 
Studies and participants 25 
  12 
From a total of 27 identified studies, we were granted access to 17 through secure online 1 
platforms, but only 11 trials reported radiographic damage progression during the second year, 2 
thus allowing inclusion in the final analyses. Reasons for the non-inclusion of 16 out of the 27 3 
trials initially identified are described in Figure 2 and Supplementary Table S1. The critical 4 
appraisal results for each of the 11 RCTs are summarized in Supplementary Figure S1 (low 5 
risk of bias in all items assessed for all the trials). We had access to data from 100% of the 6 
randomized patients in 9 out of the 11 trials and from 93% of patients in the remaining two, 7 
resulting in a total sample of 8,114 patients. Most trials tested anti-TNFα therapies (n=9), and 8 
included patients with insufficient response to MTX (n=7) and with established disease (>2 9 
years) (n=9) – Supplementary Table S2. The mean (SD) DAS28CRP3v ranged from 4.7 (0.9) 10 
to 5.3 (0.8) at baseline. The van der Heijde mTSS was used as the scoring method of 11 
radiographic damage progression in 10 of the trials. The remaining used the Genant method. 12 
The mean mTSS at baseline ranged from 5.9 (14.5) to 69.0 (55.8) (Supplementary Table S2).  13 
Altogether, 2322 patients (29%) were excluded from the final analyses (Supplementary Table 14 
S3). The main reason for exclusion was the lack of data on radiographic outcome (71% of all 15 
cases). Those excluded from these analyses were older (1.3 years on average), reported 16 
higher PGA and HAQ and had more active disease according to Physician’s global 17 
assessment. Regarding disease status at 6 or 12 months, 305 of the excluded patients had no 18 
data and the remaining 2017 had lower rates of 4V-remission and higher rates of non-19 
remission, compared with those included. 20 
 21 
Frequency of remission status, radiographic and functional outcomes 22 
A total of 5,792 (71%) patients had information on both the remission definition and on the 23 
primary outcome (radiographic progression) (Table 1). Pooled meta-analytic frequency (95% 24 
CI) of 4V-remission at 6 OR 12 months was 23.0% (18.0 to 28.0%), while for 4V-near-remission 25 
was 18.9% (15.4 to 22.1%), considering all treatment arms together (Table 1).  26 
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Good radiographic outcome was observed in 74.1% (66.2 to 82.0%) of all patients using the 1 
primary cut-off (∆mTSS≤0.5), and by 94.6% (92.9 to 96.4%) using ∆mTSS≤5 (Table 1). Good 2 
functional outcome, which could only be assessed in 8 RCTs (3,904 patients), was observed 3 
in 70.6% (66.7 to 73.5%) of all patients using the elected cut-off (∆HAQ-DI≤0.0), and by 31.1% 4 
(24.9 to 37.2%) using ∆HAQ-DI≤0.0 AND HAQ-DI≤0.5 (Table 1). 5 
 6 
Likelihood of reaching good radiographic outcome for patients in 4V-near-remission 7 
compared to patients in 4V-remission and to patients in non-remission 8 
Overall, the proportion of GRO for the primary score (∆mTSS≤0.5) was high (71.8 to 81.1%) 9 
for the three mutually-exclusive remission categories (Table 2). The proportion of patients with 10 
GRO did not differ significantly between those in 4V-near-remission and 4V-remission: -2.9% 11 
(95%CI: -7.3 to +1.5%). Patients in 4V-near-remission had a significantly higher chance of 12 
achieving GRO compared to patients in non-remission (+6.2%; 95%CI: 2.3 to 10.1%). Results 13 
for these comparisons are shown in Table 2 and Figure 3. Similar observations were made for 14 
GRO defined as ∆mTSS≤5 (Table 2). None of the differences was statistically significant when 15 
∆mTSS≤0 was used (Table 2). 16 
We performed a sensitivity analysis by excluding the three apparent outliers in Figure 3 (the 17 
DE019, GO-FURHTER, and TEMPO trials) which confirmed no significant difference in the 18 
meta-analytic RRs (∆mTSS≤0.5) between 4V-remission and 4V-near-remission (RR=0.99; 19 
95%CI 0.95 to 1.03). 20 
 21 
Likelihood of reaching good functional outcome for patients in 4V-near-remission 22 
compared to patients in 4V-remission and to patients in non-remission 23 
Overall, the proportion of GFO for the elected outcome (∆HAQ-DI≤0.0) was high (68.8 to 24 
77.6%) for the three mutually exclusive remission categories (Table 2). The proportion of 25 
patients with GFO was significantly lower in 4V-near-remission than 4V-remission: -11.0% 26 
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(95%CI: -16.3 to -5.7%). Patients in 4V-near-remission had a similar chance of achieving GFO 1 
compared to patients in non-remission (-2.2%; 95%CI: -6.8 to +2.4%). The differences 2 
between 4V-near-remission and 4V-remission were more striking for the GFO defined as 3 
ΔHAQ-DI≤0 AND HAQ-DI≤0.5: -39.6% (95%CI: -48.4 to -30.9%). The difference between 4V-4 
near-remission and non-remission was non-significant (+1.7%; 95%CI: -7.4 to +10.8).  5 
 6 
Comparison of the 4V-remission and the proposed 3V-remission regarding prediction 7 
accuracy for radiographic and functional outcome 8 
Having shown that the difference in the probability of GRO between 4V-remission and 4V-9 
near-remission, was neither statistically nor clinically relevant,[38] we were allowed to evaluate 10 
the difference between the 4V-remission and 3V-remission (the latter combining the 4V-near-11 
remission and 4V-remission) groups (Table 3). The results indicated that the likelihood ratio of 12 
having GRO (ΔmTSS≤0.5) was higher for patients in 4V-remission compared to 4V-non-13 
remission (LR+=1.36, 1.15 to 1.61) than between patients in 3V-remission vs 3V-non-14 
remission (LR+=1.26; 1.13 to 1.41), although there was a large overlap in 95%CIs. Conversely, 15 
the likelihood of having GRO in the absence of remission was significantly smaller for the 3V-16 
remission (LR-=0.86; 0.79 to 0.94) and non-significant for the 4V-remission (LR-=0.92; 0.81 to 17 
1.04) vs their counterparts (Table 3). 18 
The same comparisons were made regarding functional outcomes (Table 3). The likelihood 19 
ratio of having GFO (ΔHAQ≤0.0) was significantly higher for patients in 4V-remission 20 
compared to in 4V-non-remission (LR+=1.34, 1.16 to 1.54), while it was not significantly 21 
different between patients in 3V-remission vs 3V-non-remission (LR+=1.08; 0.99 to 1.17). 22 
Contrariwise, the likelihood of having GFO in the absence of remission was not significantly 23 
different from that for either the 3V-remission (LR-=0.94; 0.88 to 1.02) or the 4V-remission (LR-24 
=0.90; 0.79 to 1.02) vs their comparator groups (Table 3). 25 
 26 
The proportion of patients whose prediction of GRO was accurate (= TP + TN) was, overall, 27 
quite low for both definitions of remission (≤53%). It was, however, higher for the 3V-remission 28 
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definition than for the 4V-remission definition: 6.5%, 10.6%, and17.2% higher at  ΔmTSS≤0..0, 1 
≤0.5, and ΔmTSS≤5, respectively (See Figure 4). As expected, the improved accuracy of the 2 
3V-remission is a result of a substantially lower percentage of FN, i.e. patients without 3 
remission who do not have radiographic progression, at the cost of a much smaller increase 4 
in the percentage of FP, i.e. the patients with remission who do have progression. 5 
Regarding the elected definition of GFO, the proportion accurately predicted with the 3V 6 
definition (50.3%; 46.0 to 54.6) was significantly higher than with the 4V definition (43.8%; 40.9 7 
to 46.6). The percentage accurately predicted was much higher for the alternative definition of 8 
GFO, the statistically significant difference being favourable for the 4V definition. 9 
Figure 5 presents a “clinical eye’s” summary of good/bad radiographic outcomes observed 10 
according to the current and the proposed (3V) Boolean-based definitions of remission (95%CI 11 
and I2 statistics are presented in Supplementary Table S4). Overall, 73.3% (95%CI: 63.9% to 12 
81.8%) of the patients in non-4V-remission still had GRO (ΔmTSS≤0.5), and the same was 13 
observed for 71.8% (95%CI: 62.1% to 80.5%) of those in non-3V-remission. The percentages 14 
of GRO increase to 81.1% (95%CI: 74.4% to 86.9%) and 79.6% (95%CI: 72.2% to 86.1%) 15 
among those in 4V and 3V-remission, respectively. None of these differences were statistically 16 
significant.  17 
The overall proportion of patients achieving 3V-remission was almost double of those reaching 18 
4V-remission (41.9% vs 23.0%). 19 
 20 
Sensitivity analyses 21 
Adjustment to co-factors. The models adjusted for co-factors for the same comparisons 22 
showed even smaller differences between 4V-near-remission and 4V-remission categories 23 
regarding the prediction of good radiographic outcomes (Supplementary Table S5 and S6). 24 
 25 
Exploration of radiographic damage in 4V-near-remission. Within the subgroup of patients in 26 
4V-near-remission, PGA (at 6 and 12 months) is not a statistically significant predictor of 27 
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radiographic progression over 2y (RR= 1.05 per SD unit increase, 95%CI: 0.93 to 1.16); 1 
similarly, non-significant results were obtained for SJC28 and TJC28 (both 0 vs 1 in this 2 
subgroup): RR= 1.09; 95%CI 0.90 to 1.27, and RR=0.86; 95%CI 0.68 to 1.04, respectively. 3 
Only CRP was a (borderline) statistically significant predictor of radiological progression (RR = 4 
1.06, 95%CI 1.00 to 1.12). 5 
 6 
Radiographic damage progression according to PGA. In the subgroup of patients reaching 3V-7 
remission a ∆mTSS>5 units, was observed in 2.3% (95%CI: 1.0 to 4.3%) of patients scoring 8 
PGA>1 and in 1.3% (0.6 to 2.3%) of those with PGA <1. The corresponding values for 9 
∆mTSS>0.5 units were 18.4% (13.8 to 23.5%) and 15.2% (9.9 to 21.4%), respectively.  10 
(Supplementary Table S7). 11 
 12 
 13 
DISCUSSION 14 
This is the first study assessing the prevalence of 4V-near-remission in RCTs and the first 15 
comparing radiographic damage progression between patients in 4V-near-remission and in 16 
4V-remission. The pooled rate of 4V-near-remission was almost the same of 4V-remission 17 
(19% vs 23%). These mutually exclusive groups did not differ significantly in terms of 18 
subsequent radiographic damage accrual. Patients in 4V-near-remission had a significantly 19 
better radiographic outcome than those in non-remission. 20 
These observations legitimised the next step in our analyses: to explore the implications of 21 
choosing between the 3V and the 4V definitions of remission. The odds of good structural 22 
outcome were slightly higher for the 4V-remission, but without statistical, or, in our view, clinical 23 
significance. The 3V-remission showed a better performance in terms of true estimations of 24 
significant damage (i.e. sum of TP and TN estimations). If a ‘treat-to-remission’ strategy had 25 
been applied in this population, the 3V-remission definition would have prevented therapy 26 
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escalation in 19% of all participants, when compared to the 4V-remission. This would occur at 1 
the cost of having an excess of 6.1% of patients having a ΔmTSS>0.0, 4.0% of patients having 2 
a ΔmTSS>0.5 and of 0.7% having ΔmTSS>5 units. These trade-offs may be differently valued 3 
by different observers. Our proposal to use the 3V-remission definition is also rooted in solid 4 
clinical common sense: a (major) part of patients who fail remission solely because of PGA is 5 
not be expected to benefit from additional immunosuppressive therapy, as PGA does not 6 
reflect disease activity in these patients. However, clinical judgement is needed as to decide 7 
in individual patients whether the PGA level > 1 indicates residual disease activity that might 8 
be successfully treated with more intensive RA treatment, or reflects another cause, for which 9 
more intensive RA treatment would be unnecessary and potentially harmful. Guiding 10 
definitions and recommendations should always be aligned with good clinical wisdom. 11 
The data also emphasizes that all remission concepts have a relatively poor predictive value 12 
regarding radiographic damage, as shown by low LRs (although better in 4V-remission) and 13 
predictive accuracies below 53% (better in 3V-remission). This reflects the fact that 73% of 14 
patients in non-4V-remission had good radiographic outcomes and 19% of those in 4V-15 
remission still presented radiographic progression (∆mTSS>0.5). 16 
4V-remission was associated with significantly higher rates of GFO (77.6%), compared to 4V-17 
near-remission (66.9%); this latter rate is similar to that observed in non-remission (68.8%). 18 
The differences were more marked in favour of a 4V-remisision if the definition of GFO adopted 19 
by the ACR/EULAR committee was used (4V-remission=60.5%, 4V-near-remission=22.5%, 20 
and non-remission=21.2%). Positive likelihood ratios also favoured 4V-remission, while 21 
negative LRs did not reach significance in favour of 4V-near-remission. The predictive 22 
accuracy of 3V-remission for the elected functional outcome was numerically better than for 23 
4V-remission, nearly reaching statistical significance. 24 
The results regarding functional outcome demand a critical appraisal. Overall, PGA and HAQ-25 
DI are correlated to the level r = 0.5 to 0.7. In higher disease activity states, both PGA and 26 
HAQ-DI predominantly reflect disease activity. In remission, they are expected to remain 27 
correlated, even if one assumes (as we do) that neither of them substantially reflects 28 
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inflammation at this stage, because they are essentially determined by similar subjective 1 
factors and comorbidities [9, 14, 17, 39] It follows that, irrespective of disease activity, PGA is 2 
bound to predict HAQ-DI, and this obviously questions the use of HAQ-DI to assess the use 3 
of PGA, especially in a definition of remission, if it is intended to guide decisions on 4 
immunosuppressive therapy. The current results confirm this interpretation: How else could 5 
we coherently explain that, also in our study, 4V-remission is associated with significantly 6 
higher prevalence of GFO than 4V-near-remission if these two conditions share similar levels 7 
of SJC28, TJC28 and CRP (all ≤1) and similar levels of radiographic progression? The only 8 
difference is PGA.  9 
 10 
 11 
The robustness of this work is supported by (i) the use of individual patient data, allowing 12 
uniform analyses procedures, (ii) the availability of data collected under stringent RCT 13 
conditions, (iii) the inclusion of over 5,700 patients, and (iv) the use of both crude and adjusted 14 
statistical analyses. This study also has potential limitations and biases. The definition of 15 
remission was based only on two independent time-points (6 OR 12 months) and used to 16 
predict radiographic progression over the following year. Although this was also the 17 
methodology used by the ACR/EULAR group,[4] it is recognized that alternative ways exist to 18 
quantify sustained remission, which might be useful both in understanding the construct of 19 
remission and investigating its relationship with structural damage accrual.[4] Good outcome 20 
was assessed only within the second year after randomization. Although this is the efficacy 21 
endpoint used in most trials, longer follow-up assessment could provide different results.[40] 22 
When 3V-remission is agreed to be an acceptable endpoint for evaluating disease modifying 23 
treatment in RA, the ability of the 3V-remission definition to detect differences between 24 
(effective) treatments, i.e. its responsiveness, should be established and compared to that of 25 
4V-remission and other established trial endpoints in RA. Patients with missing data, excluded 26 
from the analysis, had higher PGA and HAQ-DI scores and more active disease at 6 and 12 27 
months, but they were not significantly different with regards to other factors recognised as 28 
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relevant for radiographic outcome. The exclusion of these patients might have changed the 1 
relationship between disease activity status and the outcomes under consideration in an 2 
unknown direction. It should be noted that we did not analyse within trial arms and used the 3 
data of clinical trials as in observational studies, therefore discarding the effects of 4 
randomization. As patients fulfilled inclusion criteria for RCTs, generalizability of our results is 5 
limited to patients with high disease activity starting treatment. In 7 out of the 11 RCTs, joint 6 
assessments were performed by independent assessors, and the 4 other studies did not use 7 
an independent joint assessor. We do not know whether this may have affected the 8 
(interpretation of the) results of our study in any way. Finally, some changes to the published 9 
protocol for this study need to be disclosed, namely the use of ΔmTSS≤0.5 units as the primary 10 
outcome instead of the ≤0 cut-off, for the reasons outlined in the methods section.  11 
The most relevant implications of this study for clinical practice and research relate to the most 12 
appropriate definition of remission and its use as the guiding target for therapy. Our results 13 
demonstrate that patients in 4V-near-remission do not differ significantly from those in 4V-14 
remission in terms of radiographic damage accrual, while they can be clearly separated from 15 
those in non-remission. This supports the aggregation of the first two groups, i.e. the proposed 16 
3V-remission definition. Contrary to ACR/EULAR,[4]   but in line with previous and current 17 
evidence,[13, 21, 22, 41] our results demonstrated that the 3V-remission definition does not 18 
significantly diminish the ability to predict structural damage, while it may significantly reduce 19 
the risk of overtreatment, but this should be validated in clinical settings.[19, 20] The 20 
implications of these observations should be further tested in the remission definitions based 21 
on composite indices SDAI and CDAI, as also endorsed by ACR/EULAR. 22 
The ACR/EULAR committee also addressed the 3V-definition and reached the opposite 23 
conclusion.[4]  This may be explained by differences in methodology and reasoning. First, 24 
ACR/EULAR tested one single and very strict cut-off to define good radiographic outcome 25 
(ΔmTSS≤0), which is, in our view, excessively stringent, as it does not even allow for a 26 
difference of one unit in change score in the total of 448 joints assessed by the 2 radiograph 27 
assessors, which is averaged to 0.5. Both cut-offs are well below the smallest detectable 28 
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change within one subject: 2-3 units according to an OMERACT expert panel.[38] However, in 1 
our study, the ΔmTSS≤0 was the one with more favourable results for the 4V compared to the 2 
3V-remission in terms of GRO prediction, predictive accuracy, and rate of FN, but not in LR, 3 
for which the ΔmTSS ≤0.5 was more favourable. While considering these issues, one should 4 
take into account that ΔmTSS =1 has been estimated to justify a decrease of the HAQ score 5 
of only 0.01.[42] Second, the ACR/EULAR committee limited their analysis to 4V vs 3V, which 6 
significantly overlap, thus "diluting" the characteristics of a very unique group of patients: 4V-7 
near-remission.  Also, the number of patients analysed by ACR/EULAR was much lower. 8 
Furthermore, the decision of the ACR/EULAR committee was, seemingly, strongly influenced 9 
by the much better prediction of good functional and "overall" good outcomes for the 4V- versus 10 
the 3V-remission. This position was recently reaffirmed.[22] The reasons why we disagree with 11 
this approach are presented above. Furthermore, the ACR/EULAR study analysed primarily 12 
the methotrexate-alone treatment groups of three trials, while we included all arms in each of 13 
eleven trials. This may explain why our likelihood ratios of GRO between 4V-remission and 14 
non-remission are much lower than the ACR/EULAR study, given that inhibition of radiographic 15 
damage by bDMARDs has been demonstrated even in the absence of remission, thus 16 
reducing the predictive accuracy of disease activity for radiographic damage.[43-45] However, 17 
we performed a sensitivity analysis, using data from patients in the monotherapy bDMARD 18 
arms (in 9 RCTs), which showed that bDMARDs indeed reduce structural damage, and result 19 
in GRO in the majority, but not universally. Altogether, 28% of all patients exposed to 20 
bDMARDs monotherapy presented ΔmTSS≥0.5 (11 to 57% in the individual trials; data not 21 
shown). In summary, we believe that our approach is valid and provides a better representation 22 
of current clinical practice. However, it will not fit contexts where access to bDMARDs is 23 
severely limited. Finally, the selection of tools by the ACR/EULAR committee was "based (...) 24 
on the need to include patient-reported outcomes", among other factors.[4] PGA was selected 25 
because it is associated with better prediction of the combination of radiographic and functional 26 
outcome.[4]  While this is valid in the overall spectrum of disease activity, this argument is no 27 
longer true when the disease process is under control (SJC28, TJC28 and PCR ≤1) as 28 
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demonstrated in this study and elsewhere.[17] It has been proposed to raise the cut-off value 1 
of PGA [22, 46, 47] but this is at best a partial solution: we previously found that among 4,381 2 
international patients in 3v-remission, 63% scored PGA>1, but  still 44% scored it >2, 32% >3 3 
and 0.6% scored PGA as high as 10.[17] In addition, PGA at low disease activity states is 4 
essentially determined by subjective factors and comorbidities,[9, 17, 18] in contrast to e.g. 5 
swollen joint counts and CRP. The current study shows that PGA has no significant relationship 6 
with radiographic damage progression, both by comparing the 4V and 3V remission groups 7 
and by analysing the relationship between the 2 parameters within the specific group of 8 
patients in 4V-near-remission. These observations support our view to leave it out of the 9 
treatment target definition used to control inflammation (biological remission). 10 
 11 
It has been recognized that treating to target often leaves room for improvement.[48] For 12 
patients with active disease, there is little doubt that controlling the disease is the most 13 
important means to improve the patient’s condition, both at short and long-term. Once low 14 
disease activity or remission is achieved, a persistently high disease impact should become 15 
the guiding target: after a diligent search for remaining (undetected) disease activity, it needs 16 
to be analysed and understood so as to choose the best adjunctive intervention, such as 17 
analgesia, rehabilitation or anti-depressive therapy, among other pharmacological and non-18 
pharmacological therapies.[49] PGA score is not appropriate for this purpose, and more 19 
analytic instruments, such as the Patient Reported Outcome Measurement Information System 20 
(PROMIS),[50] the RA Impact of Disease (RAID) score[51, 52] or the RA Flare 21 
Questionnaire[53] are required.  22 
Overall, these results support the proposal that the 3V definition of remission in parallel with a 23 
separate evaluation of the patient's perspective, i.e. the dual target strategy, deserves 24 
consideration. The first target aims to control of inflammation (biological remission) and the 25 
other one to control of disease impact (symptom remission), guided by clinically informative 26 
PROMs.[9, 16, 20] Pursuing and achieving the first is an important contribution, but no 27 
guarantee that the second will be fulfilled. Further research, specifically regarding adjuvant 28 
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interventions required to achieve effective control of disease impact endured by patients in 1 
biological remission designed to bring patients from 4V-near-remission into full remission is 2 
warranted to validate the concept of dual-target. Improving symptoms and signs of RA, both 3 
short and long term is the major goal of treatment and it deserves being highlighted by an 4 
independent treatment target. 5 
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Table 1 Frequency of remission and good radiographic outcome in the included studies 
Trial (year) n a 
Remission at 6 OR 12 months, n (%)  
 Good Radiographic outcome from 12 to 24 
months b, n (%) 
  Good functional outcome from 12 to 24 
months, n (%) 
4V-remission 
4V-near-
remission 
Non-
remission 
  
ΔmTSS≤0 ΔmTSS≤0.5 ΔmTSS≤5 
 
n total ΔHAQ-DI≤0c  
ΔHAQ-DI≤0 AND 
HAQ-DI ≤0.5 
DE019 (2004) 425 68 (16.0) 45 (10.6) 312 (73.4)   245 (57.6) 297 (69.9) 397 (93.4)  398 281 (70.6)  114 (28.6) 
TEMPO (2004) 442 113 (25.6) 91 (20.6) 238 (53.8)   282 (63.8) 330 (74.7) 423 (95.7)  421 300 (71.3)  152 (36.1) 
COMET (2008) 344 102 (29.7) 107 (31.1) 135 (39.2)   250 (72.7) 289 (84.0) 329 (95.6)  324 237 (73.1)  138 (42.6) 
RAPID 1 (2008) 650 177 (27.2) 143 (22.0) 330 (50.8)   424 (65.2) 508 (78.2) 636 (97.7)  642 420 (65.4)  135 (21.0) 
RAPID 2 (2009) 417 51 (12.2) 81 (19.4) 285 (68.4)   286 (68.6) 324 (77.7) 398 (95.4)  435 290 (66.7)  79 (18.2) 
GO-FORWARD (2010) 352 86 (24.4) 74 (21.0) 192 (54.6)   200 (56.8) 228 (64.8) 304 (86.4)  358 na  105 (29.3) 
GO-BEFORE (2011) 499 117 (23.5) 80 (16.0) 302 (60.5)   403 (80.8) 446 (89.4) 493 (98.8)  507 na  187 (36.9) 
LITHE (2011) 796 146 (18.3) 174 (21.9) 476 (59.8)   558 (70.1) 640 (80.4) 790 (99.2)  550 369 (67.1)  123 (22.4) 
DE013 (2013) 540 156 (28.9) 50 (9.3) 334 (61.8)   286 (53.0) 351 (65.0) 483 (89.4)  518 383 (73.9)  249 (48.1) 
GO-FURTHER (2014) 483 54 (11.2) 89 (18.4) 340 (70.4)   151 (31.3) 191 (39.5) 405 (83.9)  493 na  94 (19.1) 
FUNCTION (2016) 844 308 (36.5) 151 (17.9) 385 (45.6)   713 (84.5) 766 (90.8) 840 (99.5)  616 470 (76.3)  250 (40.6) 
Total n 
Meta-analytic %  
(95% CI) 
5,792 
 
1,378  
23.0  
(18.0 to 28.0) 
1,085  
18.9  
(15.4 to 22.1) 
3,329  
58.1  
(52.0 to 64.1) 
  3,798  
64.1  
(54.9 to 73.2) 
4,370  
74.1  
(66.2 to 82.0) 
5,498  
94.6  
(92.9 to 96.4) 
  5,262c 2,750 
70.6 
(67.7 to 73.5) 
 1,626 
31.1  
(24.9 to 37.2) 
a. Number of patients with information both on remission status and on radiographic outcome 
b. All trials used van der Heijde mTSS (0 to 448) except the LITHE trial, in which the Genant mTSS (0 to 202) was used instead. 
c. Not possible to be determined in the three golimumab trials due to changes that occurred in the research environment and stat istical software available since the initial data 
analyses (thus, n=3,904) 
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 4V-near-remission= SJC28, TJC28, CRP (in mg/dl) ≤1 and PGA (0-10)>1; 
Non-remission = SJC28 >1 OR TJC28>1 OR CRP (in mg/dl)>1 at 6 OR 12 months of follow-up in all cases; ∆mTSS = change in the modified Total Sharp 
Score  during the second year of follow-up 
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Table 2: Pooled outcomesa and measures of association between remission categories and good 
radiographic and good functional outcomes, during the second year of follow-up. 
Good Radiographic Outcome (GRO) defined as ∆mTSS≤0.5 
 
4V-remission 
(n=1,378) 
4V-near-remission 
(n=1,085) 
Non-remission 
(n=3,329) 
Percentage GRO (95% CI) 81.1 (74.4 to 86.9) 78.2 (69.5 to 85.8) 71.8 (62.1 to 80.5) 
   
 
4V-near-remission vs  
4V-remission 
4V-near-remission vs  
Non-remission 
∆ percentage GRO (95% CI) −2.9 (−7.3 to 1.5) 6.2 (2.3 to 10.1) 
Relative Risk GRO (95% CI) 0.98 (0.94 to 1.02) 1.07 (1.02 to1.12) 
Good Radiographic Outcome (GRO) defined as ∆mTSS≤0 
 4V-remission 4V-near-remission Non-remission 
Percentage GRO (95% CI) 71.5 (63.5 to 78.8) 64.1 (54.6 to 73.2) 62.2 (51.5 to 72.4) 
   
 
4V-near-remission vs  
4V-remission 
4V-near-remission vs  
Non-remission 
∆ percentage GRO (95% CI) -7.7 (-16.6 to 1.1) 1.7 (-8.1 to 11.5) 
Relative Risk GRO (95% CI) 0.91 (0.82 to 1.02) 1.04 (0.94 to 1.16) 
 Good Radiographic Outcome (GRO) defined as ∆mTSS≤5 
 4V-remission 4V-near-remission Non-remission 
Percentage GRO (95% CI) 97.5 (95.4 to 98.9) 96.1 (92.5 to 98.5) 94.2 (90.2 to 97.2) 
   
 
4V-near-remission vs 
4V-remission 
4V-near-remission vs  
Non-remission 
∆ percentage GRO (95% CI) -2.5 (-7.5 to 2.6) 4.1 (0.7 to 7.6) 
Relative Risk GRO (95% CI) 99.9 (0.97 to 1.01) 1.01 (1.00 to 1.02) 
Good Functional Outcome (GFO) defined as ΔHAQ-DI≤0 
 
4V-remission 
(n=1,041) 
4V-near-remission 
(n=758) 
Non-remission 
(n=2,105) 
Percentage GFO (95% CI) 77.6 (74.3 to 80.8) 66.9 (62.6 to 71.2) 68.8 (66.0 to 71.7) 
   
 
4V-near-remission vs  
4V-remission 
4V-near-remission vs  
Non-remission 
∆ percentage GFO (95% CI) -11.0 (-16.3 to -5.7) -2.2 (-6.8 to 2.4) 
Relative Risk GFO (95% CI) 0.87 (0.81 to 0.94) 0.98 (0.92 to 1.04) 
Good Functional Outcome (GFO) defined as ΔHAQ-DI≤0 AND HAQ-DI≤0.5 
 
4V-remission 
(n=1,305) 
4V-near-remission 
(n=1,003) 
Non-remission 
(n=2,954) 
Percentage GFO (95% CI) 60.2 (53.3 to 67.0) 22.5 (15.9 to 29.1) 21.2 (16.1 to 26.3) 
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4V-near-remission vs  
4V-remission 
4V-near-remission vs  
Non-remission 
∆ percentage GFO (95% CI) −39.6 (−48.4 to -30.9) 1.7 (-7.4 to 10.8) 
Relative Risk GFO (95% CI)                   0.37 (0.30 to 0.46)                    1.12 (0.82 to 1.53) 
 
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 4V-near-remission= SJC28, TJC28, 
CRP (in mg/dl) ≤1 and PGA (0-10)>1; Non-remission = SJC28 >1 OR TJC28>1 OR CRP (in  mg/dl)>1, irrespective 
of PGA value; at 6 OR 12 months of follow-up in all cases; ∆mTSS = change in the modified Total Sharp Score 
during the second year of follow-up; GRO = Good Radiographic Outcome. 
 
a. Determined by meta-analyses: for each trial, we calculated the differences in the proportion/chance (∆ proportion) 
of GRO or GFO between 4V-near-remission and 4V-remission states and between 4V-near-remission and non-
remission states; then, we pooled these differences with a random effects model to obtain an overall estimate of the 
difference (with 95%CI). 
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Table 3. Meta-analyses of good outcomes likelihood ratios for the 4V- and 3V-
remission status. 
Good Outcome a  4V-Remission 
(versus non-4V) 
I2  
LR+ 
LR- 
 3V-Remission 
(versus non-3V) 
I2  
LR+ 
LR- 
 LR+ 
(95% CI) 
LR- 
(95% CI) 
 LR+ 
(95% CI) 
LR- 
(95% CI) 
ΔmTSS≤ 0.5 
 
1.36 
(1.15 to 1.61) 
0.92 
(0.81 to 1.04) 
38% 
0% 
 
1.26 
(1.13 to 1.41) 
0.86 
(0.79 to 0.94) 
40% 
3% 
ΔmTSS≤ 0 
 
1.32 
(1.17 to 1.50) 
0.91 
(0.82 to 1.02) 
19% 
0% 
 
1.20 
(1.12 to 1.29) 
0.87 
(0.81 to 0.93) 
0% 
0% 
ΔmTSS≤ 5 
 
1.40 
(0.88 to 2.23) 
1.01 
(0.76 to 1.33) 
56% 
0% 
 
1.33 
(1.03 to 1.71) 
0.92 
(0.77 to 1.10) 
40% 
0% 
ΔHAQ-DI ≤0 
 1.34 
(1.16 to 1.54) 
0.90 
(0.79 to 1.02) 
18% 
0% 
 
1.08 
(0.99 to 1.17) 
0.94 
(0.88 to 1.02) 
17% 
0% 
ΔHAQ-DI ≤0 AND 
HAQ-DI ≤0.5 
 3.35 
(2.78 to 4.03) 
0.60 
(0.52 to 0.68) 
72% 
45% 
 
1.82 
(1.59 to 2.07) 
0.55 
(0.47 to 0.65) 
80% 
87% 
a. n=5,792 for ΔmTSS, n=3,904 for ΔHAQ-DI≤0 and  n= 5,262 for ΔHAQ-DI≤0 AND HAQ-
DI≤0.5,  
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 3V-
remission= SJC28, TJC28, CRP (in mg/dl) ≤1; Non-remission = SJC28 >1 OR TJC28>1 OR 
CRP (in mg/dl)>1, irrespective of PGA value; at 6 OR 12 months of follow-up in all cases 
∆mTSS = change in the modified Total Sharp during the second year of follow-up. LR+ = 
Positive Likelihood Ratio; LR- = Negative Likelihood Ratio. I2: heterogeneity index. 
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FIGURE CAPTIONS  
 
Figure 1 – Definitions of remission tested in the study  
 
Legend: SJC28 = swollen 28-joint count, range 0-28; TJC28 = tender 28-joint count, 
range 0-28; CRP = C-reactive protein, mg/dl; PGA = patient global assessment, range 0-
10 = worst. 
Footnote: In general, in no remission states, disease-modifying antirheumatic drug 
(DMARD) therapy will be intensified, while at remission states, DMARD therapy will 
be unchanged or tapered. The no remission/4V-near-remission state (hatched) has a risk 
of overtreatment, if DMARD therapy is intensified. 
 
 
 
Figure 2 - Flowchart with the process of study identification and data access 
 
 
 
Figure 3 – Meta-analyses of risk ratio of obtaining good radiographic outcome 
(∆mTSS≤0.5 units); 4V-near-remission vs 4V-remission and vs Non-remission. 
 
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 4V-
near-remission= SJC28, TJC28, CRP (in mg/dl) ≤1 and PGA (0-10)>1; Non-remission 
= SJC28 >1 and/or TJC28>1 and/or CRP (in mg/dl)>1, irrespective of PGA value; at 6 
OR 12 months of follow-up in all cases; ∆mTSS = change in the modified Total Sharp 
Score during the second year of follow-up. 
 
 
Figure 4 - Pooled meta-analytic prediction accuracy of 4V- and 3V-remission status for 
the good radiographic and functional outcomes  
 
Footnote: The sum of the meta-analytic percentages of TP, FN, FP, and TN is slightly 
less than 100% due to error estimation when multi-category (k>2) prevalence is 
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estimated.[35] All meta-analyses used double arcsine transformation as the preferred 
method to correct this situation.[35] 
The panels from A to F include 5,792 analysed patients (11 RCTs), E and F include 
3,904 (8 RCTs), and G and H 5,262 analysed patients (11 RCTs). 
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 3V-
remission= SJC28, TJC28, CRP (in mg/dl) ≤1; ∆mTSS = change in the modified Total 
Sharp Score from 12 months to 24 months. TP = True Positive; TN = True Negative; FP 
= False Positive; FN = False Negative; Accurately predicted = TP + TN. Between 
brackets is the pooled 95% confidence interval. 
 
 
Figure 5 – Reclassification of remission status and respective radiographic outcomes 
(n=5,792). Percentages were calculated through meta-analyses. 
 
Footnote: Excluding PGA from the remission of remission (3V-remission) almost 
duplicated the percentage of patients in remission but showed only a slight increase in 
the rate of bad outcome when compared with 4V-remission. The radiographic outcome 
in the group of patients who had no overt signs of inflammation but who presented with 
high PGA (4V-near-remission) was also not statistically different from patient in 4V-
remission.  
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 4V-
near-remission= SJC28, TJC28, CRP (in mg/dl) ≤1 and PGA (0-10)>1; Non-remission 
= SJC28 >1 AND/OR TJC28>1 AND/OR CRP (in mg/dl)>1, irrespective of PGA 
value; 3V-remission= SJC28, TJC28, CRP (in mg/dl) ≤1; All definitions as observed at 
6 OR 12 months. ∆mTSS = change in the modified Total Sharp Score during the second 
year of follow-up. 
Note: Confidence intervals and I2 statistics of pooled radiographic outcomes can be 
found in Supplementary Table S4. 
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Figure 1 – Definitions of remission tested in the study  
 
 
Legend: SJC28 = swollen 28-joint count, range 0-28; TJC28 = tender 28-joint count, range 0-28; CRP = C-
reactive protein, mg/dl; PGA = patient global assessment, range 0-10 = worst. 
Footnote: In general, in no remission states, disease-modifying antirheumatic drug (DMARD) therapy will 
be intensified, while at remission states, DMARD therapy will be unchanged or tapered. The no 
remission/4V-near-remission state (hatched) has a risk of overtreatment, if DMARD therapy is intensified. 
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Figure 2 – Flowchart with process of study identification and data access 
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Figure 3 – Meta-analyses of risk ratio of obtaining good radiographic outcome 
(∆mTSS≤0.5 units); 4V-near-remission vs 4V-remission and vs Non-remission. 
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 4V-near-
remission= SJC28, TJC28, CRP (in mg/dl) ≤1 and PGA (0-10)>1; Non-remission = SJC28 >1 
OR TJC28>1 OR CRP (in mg/dl)>1, irrespective of PGA value; at 6 OR 12 months of follow-up 
in all cases; ∆mTSS = change in the modified Total Sharp Score during the second year of 
follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Pooled meta-analytic prediction accuracy of 4V- and 3V-remission status for 
the good radiographic and functional outcomes  
 
 
Footnote: The sum of the meta-analytic percentages of TP, FN, FP, and TN is slightly less than 
100% due to error estimation when multi-category (k>2) prevalence is estimated.[35] All meta-
analyses used double arcsine transformation as the preferred method to correct this situation.[35] 
The panels from A to F include 5,792 analysed patients (11 RCTs), E and F include 3,904 (8 
RCTs), and G and H 5,262 analysed patients (11 RCTs). 
 
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 3V-remission= 
SJC28, TJC28, CRP (in mg/dl) ≤1; ∆mTSS = change in the modified Total Sharp Score from 12 
months to 24 months. TP = True Positive; TN = True Negative; FP = False Positive; FN = False 
Negative; Accurately predicted = TP + TN. Between brackets is the pooled 95% confidence 
interval. 
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Figure 5 – Reclassification of remission status and respective radiographic outcomes 
(n=5,792). Percentages were calculated through meta-analyses. 
 
Footnote: Excluding PGA from the remission of remission (3V-remission) almost duplicated the 
percentage of patients in remission but showed only a slight increase in the rate of bad outcome 
when compared with 4V-remission. The radiographic outcome in the group of patients who had 
no overt signs of inflammation but who presented with high PGA (4V-near-remission) was also 
not statistically different from patient in 4V-remission.  
 
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 4V-near-
remission= SJC28, TJC28, CRP (in mg/dl) ≤1 and PGA (0-10)>1; Non-remission = SJC28 >1 
AND/OR TJC28>1 AND/OR CRP (in mg/dl)>1, irrespective of PGA value; 3V-remission= SJC28, 
TJC28, CRP (in mg/dl) ≤1; All definitions as observed at 6 OR 12 months. ∆mTSS = change in 
the modified Total Sharp Score during the second year of follow-up. 
 
Note: Confidence intervals and I2 statistics of pooled radiographic outcomes can be found in  
Supplementary Table S4. 
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Supplementary Table S1 – Overview of data requested, obtained and used, with 
reasons for non-inclusion  
Platform used Trials requested Data 
obtained 
Data 
used 
Reasons for not being provided 
(if known) or for not being used 
Abbvie’s own 
platform1 
PREMIER - NCT00195663  yes yes  
DE019 - NCT00195702  yes yes  
Pfizer’s own 
platform2 
TEAR - NCT00259610  
no no 
The Sponsor was University of 
Alabama at Birmingham. Data not 
available. 
COMET - NCT00195494  yes yes  
CAMEO - NCT00654368  
no no 
The Sponsor was Amgen. Data not 
available. 
PRIZE - NCT00913458  
no no 
It was a tapering trial (dose 
reduction) 
TEMPO - NCT00393471  yes yes  
PRESERVE - NCT00565409  
yes no 
It was a tapering trial (dose 
reduction) 
ERA - NCT00356590  
no no 
The Sponsor was Amgen. Data not 
available. 
ORAL START - NCT01039688  
no no 
Delays in the process, which was 
eventually cancelled. 
ORAL SCAN - NCT00847613  
no no 
Delays in the process, which was 
eventually cancelled. 
The YODA 
project 3 – data 
from Johnson 
& Johnson 
GO BEFORE - NCT00264537  yes yes  
GO FORWARD - 
NCT00264550  
yes yes 
 
GO FURTHER - 
NCT00973479  
yes yes 
 
ATTRACT - NCT00269867  
yes no 
The radiographic data was 
provided too late (after change in 
the platform has occurred) 
ClinicalStudy-
DataRequest4 
– data from 
Roche 
ASPIRE - NCT00236028 
no no 
The Sponsor was Centocor. Data 
not available in the Sharing Data 
Platform 
LITHE - NCT00106535  yes yes  
FUNCTION - NCT01007435  yes yes  
BREVACTA - NCT01232569  yes no Only 1y data was provided 
ACT-RAY - NCT00810199  
no no 
Tested discontinuation of therapy 
in the 2nd year of trial. 
SAMURAI - NCT00144508  yes no Only 1y data was provided 
SURPRISE - NCT01120366  
no no 
The Sponsor was “SURPRISE 
Study Group”. Data not available in 
Supplementary file for Ferreira RJO et al. “Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient 
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the Sharing Data Platform. Linked 
with ACT-RAY study. 
REFLEX - NCT00468546/ 
NCT02097745 
yes no 
The protocol did include week 104 
assessment of radiographic score. 
Also, very difficult to match visit 
date with visit number. 
IMAGE - NCT00299104  yes No Only safety data was provided 
ClinicalStudy-
DataRequest5– 
data from UCB 
RAPID 1 - NCT00152386  yes yes  
RAPID 2 - NCT00160602/ 
NCT00175877  
yes yes 
 
C-OPERA - NCT01451203  
no no 
The Sponsor was Astellas. Data 
not available in the Sharing Data 
Platform. 
 
1 – https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-
sharing-with-qualified-researchers.html - meanwhile transitioned to Vivli (https://vivli.org/) 
2 - https://www.pfizer.com/science/clinical-trials/trial-data-and-results/data-requests  - meanwhile transitioned to Vivli 
(https://vivli.org/) 
3 - https://yoda.yale.edu/ meanwhile transitioned to Microsoft Online. 
4 - https://www.clinicalstudydatarequest.com/Default.aspx 
5 - https://www.clinicalstudydatarequest.com/Default.aspx, meanwhile transitioned to Vivli (https://vivli.org/) 
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Supplementary Figure S1 – Risk of bias assessment of the 11 RCTs  
 
Footnote: To appraise the quality of the trials we assessed different papers[1-17] 
resulting from the same trial (e.g. reporting outcomes for different timepoints). We also 
assessed the full protocols provided by the sponsors and requested additional 
information to individual authors when needed. 
 
References: 
1 Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional 
outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal 
antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate 
therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. 
2 Keystone EC, van der Heijde D, Kavanaugh A, et al. Clinical, functional, and radiographic 
benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding 
rheumatoid arthritis. J Rheumatol 2013;40:1487-97. 
Supplementary file for Ferreira RJO et al. “Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient 
global assessment: an individual data meta-analysis of 5792 patients” 
 43 
3 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, 
randomized, double-blind clinical trial of combination therapy with adalimumab plus 
methotrexate versus methotrexate alone or adalimumab alone in patients with early, 
aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis 
Rheum 2006;54:26-37. 
4 Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of 
etanercept and methotrexate compared with each treatment alone in patients with 
rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81. 
5 van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and 
methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical 
and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis 
Rheum 2006;54:1063-74. 
6 Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a 
combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid 
arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-
82. 
7 Keystone E, Heijde D, Mason D, Jr., et al. Certolizumab pegol plus methotrexate is 
significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: 
findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-
controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29. 
8 Keystone EC, Combe B, Smolen J, et al. Sustained efficacy of certolizumab pegol added to 
methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. 
Rheumatology (Oxford) 2012;51:1628-38. 
9 Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus 
methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. 
Ann Rheum Dis 2009;68:797-804. 
10 Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid 
arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann 
Rheum Dis 2010;69:1129-35. 
11 Keystone EC, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid 
arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study 
extension. J Rheumatol 2013;40:1097-103. 
12 Emery P, Fleischmann RM, Doyle MK, et al. Golimumab, a human anti-tumor necrosis factor 
monoclonal antibody, injected subcutaneously every 4 weeks in patients with active 
rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, 
and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-
controlled study. Arthritis Care Res (Hoboken) 2013;65:1732-42. 
13 Bingham CO, 3rd, Mendelsohn AM, Kim L, et al. Maintenance of Clinical and Radiographic 
Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis 
Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label 
Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. 
Arthritis Care Res (Hoboken) 2015;67:1627-36. 
14 Weinblatt ME, Westhovens R, Mendelsohn AM, et al. Radiographic benefit and maintenance 
of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid 
arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, 
multicentre, double blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis 
2014;73:2152-9. 
15 Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in 
rheumatoid arthritis patients with inadequate responses to methotrexate: results from the 
double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety 
and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21. 
16 Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage 
and improves physical function in patients with rheumatoid arthritis and inadequate 
responses to methotrexate: LITHE study 2-year results. J Rheumatol 2013;40:113-26. 
17 Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab combination therapy or 
monotherapy or methotrexate monotherapy in methotrexate-naive patients with early 
rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-
controlled FUNCTION trial. Ann Rheum Dis 2017;76:1279-84. 
Supplementary file for Ferreira RJO et al. “Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual data meta-analysis of 5792 patients” 
 44 
Supplementary Table S2 - Baseline characteristics of the population samples of the studies (all placebo-controlled)  
Trial name 
(Year of publication) 
DE019 
(2004) 
TEMPO 
(2004) 
COMET 
(2008) 
RAPID 1 
(2008) 
RAPID 2 
(2009) 
GO 
FORWARD 
(2010) 
GO 
BEFORE 
(2011) 
LITHE 
(2011) 
DE013 
(2013) 
GO 
FURTHER 
(2014) 
FUNCTION 
(2016) 
Biologic agent Adalimumab Etanercept Etanercept Certolizumab Certolizumab Golimumab Golimumab Tocilizumab Adalimumab Golimumab Tocilizumab 
Inclusion criteria MTX-IR csDMARD-IR a MTX-naive MTX-IR MTX-IR MTX-IR MTX-naive MTX-IR MTX-naive MTX-IR MTX-IR 
No. patients randomized 619 686 542 982 619 444 637 1196 799 592 1162 
No patients available for 
this IPD study 
619 684 542 857 582 444 637 1196 799 592 1162 
No.(%) patients with pre-
dictors and outcome at 2y 
425 (68.6) 442 (64.6) 344 (63.5) 650 (75.8) 417 (71.6) 352 (79.3) 499 (78.3) 796 (66.6) 540 (67.6) 483 (81.6) 844 (60.3) 
Demographics b            
Female (%) 74.8 75.6 73.5 82.3 80.8 81.2 83.6 83.2 73.7 81.4 79.6 
   Mean age (yrs) 55.4 (12.0) 51.9 (12.5) 51.7 (13.7) 51.8 (11.5) 50.8 (11.5) 50.2 (11.0) 49.9 (12.0) 51.9 (11.9) 52.2 (13.4) 51.4 (11.8) 49.9 (12.9) 
   Mean RA duration (yrs) 10.8 (9.0) 6.3 (5.0) 7.4 (5.4) 6.3 (4.3) 6.0 (4.1) 6.4 (6.5) b 2.5 (3.8) b 9.5 (7.8) 0.7 (0.8) 4.3 (4.9) b 0.5 (0.5) 
RF positive (%) 84.9 66.1 95.8 83.5 77.0 83.0 81.0 82.0 85.4 90.9 90.6 
Disease activity 
measures 
           
   Mean DAS28CRP3v 4.9 (0.7) 5.3 (0.8) 4.9 (0.9) 5.3 (0.7) 5.2 (0.7) 4.6 (0.8) 4.7 (0.9) 4.8 (1.0) 5.3 (0.8) 4.9 (0.8) 4.9 (0.9) 
   Mean CRP (mg/dl) 1.8 (1.9) 2.7 (3.1) 3.6 (3.6) 2.5 (2.7) 2.4 (2.5) 1.7 (2.1) 2.4 (3.0) 2.2 (2.5) 3.8 (3.9) 2.5 (2.5) 2.5 (2.9) 
   Mean TJC28 14.5 (6.4) 18.0 (6.7) 13.8 (7.1) 17.7 (6.1) 17.9 (6.4) 13.5 (7.3) 14.2 (7.3) 14.7 (7.6) 16.8 (6.3) 14.8 (6.4) 15.8 (7.3) 
   Mean SJC28 13.2 (5.5) 15.0 (5.8) 12.0 (6.2) 14.8 (5.4) 14.3 (5.6) 9.8 (5.6) 10.4 (6.0) 11.5 (6.2) 14.4 (5.7) 10.9 (5.2) 11.7 (6.0) 
   Mean PGA (cm) 5.2 (2.2) 6.9 (1.7) c 6.5 (1.9) c 6.3 (1.9) 6.0 (2.1) 5.4 (2.4) 6.0 (2.3) 5.7 (2.4) 6.4 (2.4) 6.5 (1.8) 6.5 (2.2) 
   Mean (PhGA) (cm) 6.1 (1.7) 6.6 (1.5) c 6.5 (1.5) c 6.3 (1.5) 6.4 (1.4) 5.7 (1.7) 6.2 (1.7) 5.7 (2.2) 6.5 (1.8) 6.2 (1.6) 6.3 (1.8) 
Functional status            
Mean baseline score 1.4 (1.4) 1.7 (0.6) 1.6 (1.6) 1.6 (0.6) 1.6 (0.6) 1.4 (0.8) 1.5 (0.6) 1.4 (0.6) 1.5 (0.6) 1.6 (0.7) 1.5 (0.7) 
Radiographic scores d            
   Mean baseline score 69.0 (55.8) 35.7 (49.7) 8.4 (16.2) 48.2 (57.1) 34.2 (46.3) 34.5 (48.9) 15.8 (28.9) 30.3 (30.9) 19.9 (21.0) 49.6 (55.7) 5.9 (14.5) 
a. Other than Methotrexate     
b. There was no imputation of missing data. The most frequent missing result was disease duration (11.9%; except for the three Golimumab trials for which this variable was missing in >50% of 
patients) followed by rheumatoid factor status (2.1%).  
c. Assessed with numeric rating scale (0 to 10) and not with visual analogue scale (0 to 10cm)      
d. All trials used Sharp van der Heijde mTSS (0 to 448) except in the LITHE trial, in which Genant mTSS (0 to 202) was used instead.  
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Legend: MTX - Methotrexate, IR- Insufficient responder, IPD - Individual patient data, RA, rheumatoid arthritis, RF, Rheumatoid Factor, DAS28CRP3v, Disease Activity Score with 28-joint counts, 
using c-Reactive protein and 3 variables; CRP, C-Reactive Protein, TJC28, Tender 28-joint counts; SJC28, Swollen 28-joint counts; PGA, Patient Global Assessment of disease activity; PhGA, 
Physician Global Assessment of disease activity. 
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Supplementary Table S3 - Comparison (through meta-analysis) between patients 
included and excluded from analyses. 
 Included (n=5,792) a Excluded (n=2,322) Difference (95%CI)b 
       n   Estimate (95%CI) n Estimate (95%CI)  
Baselines features 
Female (%) 5,792 79% (77 to 81) 2,322 79% (76 to 81) 0% (-2.2 to 2.6) 
Age (yrs) 5,792 51.4 (50.5 to 52.4) 2,320 52.8 (51.6 to 54.0) 1.3 (0.5 to 2.0) 
Disease duration (yrs) 5,102 5.6 (4.5 to 6.7) 2,086 5.6 (4.5 to 6.7) 0.03 (-0.18 to 0.23) 
RF positive (%) 5,666 84% (80 to 88) 2,212 82% (76 to 87) 4% (-0.3 to 7.5) 
DAS28CRP3V 5,781 4.98 (4.83 to 5.13) 2,260 5.03 (4.88 to 5.18) 0.04 (-0.01 to 0.08) 
CRP (mg/dl) 5,781 2.54 (2.23 to 2.85) 2,262 2.73 (2.30 to 3.16) 0.11 (-0.03 to 0.25) 
TJC28 5,792 15.6 (14.6 to 16.6) 2,268 16.0 (15.1 to 16.9) 0.29 (-0.03 to 0.63) 
SJC28 5,792 12.6 (11.5 to 13.6) 2,268 12.7 (11.7 to 13.8) 0.11 (-0.17 to 0.39) 
PGA (cm) 5,775 6.1 (5.8 to 6.4) 2,252 6.5 (6.2 to 7.8) 0.34 (0.21 to 0.47) 
PhGA (cm) 5,771 6.2 (6.1 to 6.4) 2,257 6.4 (6.2 to 6.6) 0.16 (0.07 to 0.25) 
mTSS 5,792 30.0 (20.8 to 39.2) 1,451c 29.6 (19.8 to 39.5) -0.03 (-1.47 to 1.41) 
HAQ-DI d 4,392 1.54 (1.46 to 1.61) 1,897 1.66 (1.59 to 1.67) 0.12 (0.09 to 0.16) 
Randomization arm % (95% CI) e 
Placebo 349 69% (60 to 77) 161 31% (23 to 40) 
P=0.68f 
 
MTX mono 935 64% (57 to 70) 524 36% (30 to 43) 
bDMARD mono 1,684 70% (65 to 74) 683 30% (26 to 35) 
DMARD and MTX 1,543 71% (69 to 74) 628 28% (25 to 31) 
Remission at 6 OR 12 months, % (95% CI) 
4V-remission 5,792 23 (18 to 28) 2,017 11 (9 to 13) -16 (-21 to -11.3) 
4V-near-remission  5,792 19 (15 to 22) 2,017 12 (9 to 16) -8 (-6 to -11) 
Non-remission 5,792 58 (52 to 64) 2,017 76 (72 to 81) 20 (16 to 24) 
 
In bold are presented the differences of which the 95%CI do not include zero, in general indicating statistical 
significance 
Legend: 95%CI, 95% Confidence Interval, HAQ-DI, Health Assessment Questionnaire – Disability Index, 
mTSS, modified Total Sharp Score, RF, Rheumatoid Factor, DAS28CRP3v, Disease Activity Score with 28-
joint counts, using c-Reactive protein and 3 variables; CRP, C-Reactive Protein, TJC28, Tender 28-joint 
counts; SJC28, Swollen 28-joint counts; PGA, Patient Global Assessment of disease activity; PhGA, 
Physician Global Assessment of disease activity. 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA 
(0-10), all ≤1; 4V-near-remission= SJC28, TJC28, CRP (in mg/dl) ≤1 and PGA (0-10)>1; Non-remission = 
SJC28 >1 OR TJC28>1 OR CRP (in mg/dl)>1, irrespective of PGA value; at 6 OR 12 months of follow-up in 
all cases. 
a. There was no imputation of missing data. The most frequently missing result was disease duration 
(11.9%), followed by rheumatoid factor status (2.1%). 
b. The difference in percentages/mean may not match exactly with (raw) arithmetic difference because all 
estimates were determined using meta-analyses with double arcsine transformation.(1) 
c. The number of missing patients was not possible to be determined in GO-FURTHER trial 
d. Not possible to be determined in the three golimumab trials due to changes that occurred in the research 
environment and statistical software available since the initial data analyses. 
e. Not possible to be determined in the three golimumab trials due to changes that occurred in the research 
environment and statistical software available since the initial data analyses; Placebo arm in 3 trials, MTX 
arm in 5 trials, bDMARD mono in 6 trials, bDMARD and MTX arm in 6 trials. When tested, the different 
dosages of bDMARD were considered in the same group 
f. The distributions of included and excluded patients per randomization treatment arm are not statistically 
significant, according to Pearson’s Chi Square test  
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Supplementary Table S4 - Pooled meta-analytic frequency of radiographic outcomes 
(with 95%CI) and heterogeneity statistics for each remission definition (n=5,792). This 
table provides complementary information to Figure 5 in the article. 
∆mTSS 
cut-off 
Remission 
Definition 
% Good Outcome 
I2 
 % Bad Outcome 
I2 
Pooled 
95%CI 
Lower 
95%CI 
Higher 
 
Pooled 
95%CI 
Lower 
95%CI 
Higher 
≤0.5 4V-rem. 81.1 74.4 86.9 88.6  18.9 13.1 25.6 88.6 
Non-4V-rem. 73.3 63.9 81.8 97.7  26.7 18.2 36.1 97.9 
4V-near-rem. 78.2 69.5 85.8 90.8  21.8 14.2 30.5 90.8 
3V-rem. 79.6 72.2 86.1 94.7  20.4 13.9 27.8 94.7 
Non-3V-rem. 71.8 62.1 80.5 97.2  28.2 19.5 37.9 97.2 
           
≤5 4V-rem. 97.5 95.4 98.9 76.2  2.5 1.1 4.6 76.2 
Non-4V-rem. 94.7 90.8 97.6 96.2  5.3 2.4 9.2 92.2 
4V-near-rem. 96.1 92.5 98.5 85.0  3.9 1.5 7.5 85.0 
3V-rem. 96.9 94.2 98.8 90.7  3.1 1.2 5.8 90.7 
Non-3V-rem. 94.2 90.2 97.2 94.8  5.8 2.8 9.8 94.8 
Legend: rem.: remission. 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 
4V-near-remission= SJC28, TJC28, CRP (in mg/dl) ≤1 and PGA (0-10)>1; Non-remission = 
SJC28 >1 AND/OR TJC28>1 AND/OR CRP (in mg/dl)>1, irrespective of PGA value; 3V-
remission= SJC28, TJC28, CRP (in mg/dl) ≤1; All definitions as observed at 6 OR 12 months. 
∆mTSS = change in the modified Total Sharp Score during the second year of follow-up. 
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Supplementary Table S5 - Meta-analyses of the adjusteda odds ratios to compare the 
predictive value of good radiographic and good functional outcomes between patients in 
4V-remission and in 4V-near-remission status (at 6 OR 12 months) 
Good Radiographic Outcome  
(from 12 to 24 months) 
No. studies 
(participants) 
4V-near-
remission 
4V-remission I2 
(Reference) OR (95% CI) 
ΔmTSS ≤ 0.5 11 (5,653) 1.00 0.97 (0.69 to 1.23) 0% 
ΔmTSS ≤ 0 11 (5,653) 1.00 1.06  (0.81 to 1.30) 0% 
ΔmTSS ≤ 5 7 (3,109)b 1.00 0.85  (0.02 to 2.19) 0% 
ΔHAQ-DI≤ 0 8 (3,696) 1.00 1.28 (0.94 to 2.05) 0% 
ΔHAQ-DI ≤0 AND HAQ-DI ≤0.5 11 (5,049) 1.00 3.47 (2.36 to 4.91) 33% 
a. Model adjusted to age at baseline, gender, rheumatoid factor, disease duration (except for 
GOBEFORE, GOFORWARD, and GOFURTHER trials as these had missing data>50%) 
radiographic damage at baseline, and treatment arm were included as possible confounders. 
b. Without GOBEFORE, LITHE, FUNCTION, and RAPID2 trials due to invalid data obtained from 
logistic regressions.  
 
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 4V-near-
remission= SJC28, TJC28, CRP (in mg/dl) ≤1 and PGA (0-10)>1; All definitions as observed at 6 
OR 12 months. ∆mTSS = change in the modified Total Sharp Score during the second year of 
follow-up; OR= Odds Ratio. 
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Supplementary Table S6 - Meta-analyses of the adjusteda odds ratios to descriptively compare the predictive value of good outcomes between 
patients in 4V-remission and in 3V-remission status (6 OR 12 months) 
 
Definition of Good Outcome 
(from 12 to 24 months) 
No. studies 
(participants) 
 4V-remission Non-remission 
I2 
 3V-remission Non-remission 
I2 
 (Reference) OR (95% CI)  (Reference) OR (95% CI) 
ΔmTSS ≤ 0.5 11 (5,653) 
 
1.00 0.66 (0.50 to 0.85) 34% 
 
1.00 0.64 (0.54 to 0.77) 0% 
ΔmTSS ≤ 0 11 (5,653)  1.00 0.68 (0.54 to 0.84) 40%  1.00 0.73 (0.64 to 0.83) 0% 
ΔmTSS ≤ 5 8 (3,607)b  1.00 0.22 (0.05 to 0.44) 0%  1.00 0.79 (0.47 to 1.12) 0% 
ΔHAQ-DI≤ 0 8 (3,696)  1.00 0.63 (0.51 to 0.76) 0%  1.00 0.72 (0.60 to 0.85) 0% 
ΔHAQ-DI≤ 0 AND HAQ-DI≤ 0.5 11 (5,049)  1.00 0.17 (0.13 to 0.22) 51%  1.00 0.30 (0.24 to 0.37) 40% 
a. adjusted analysis to: age at baseline, gender, rheumatoid factor, disease duration (except for GOBEFORE, GOFORWARD, and GOFURTHER trials as these 
had missing data>50%) radiographic damage at baseline, and treatment arm were included as possible confounders.  
b – Without LITHE, FUNCTION, RAPID2 trials due to invalid data obtained from logistic regressions. 
Legend: 4V-remission = SJC28, TJC28, CRP (in mg/dl), and PGA (0-10), all ≤1; 3V-remission= SJC28, TJC28, CRP (in mg/dl) ≤1; Non-remission = SJC28 >1 
AND/OR TJC28>1 AND/OR CRP (in mg/dl)>1, irrespective of PGA value; All definitions as observed at 6 OR 12 months. ∆mTSS = change in the modified Total 
Sharp Score during the second year of follow-up; OR = Odds Ratio.
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Supplementary Table S7. Proportion of patients in 3v-remission who have 
radiographic damage progression ≥0.5 and ≥5 according to PGA1 score ≤1 OR >1.  
Trial 
N total  
Patients with ∆mTSS>0.5 AND 
p-value2 
Patients with ∆mTSS>5 AND 
p-value2 
PGA≤1 PGA>1 PGA≤1 PGA>1 
n % n %  n % n %  
DE019 114 13/43 30.2 14/71 19.7 0.26 1/43 2.3 5/71 7.0 0.40 
TEMPO 204 8/63 12.7 33/141 23.4 0.09 2/63 3.2 5/141 3.6 1.0 
COMET 200 3/45 6.7 18/155 11.6 0.42 0/45 0 6/155 3.9 0.34 
RAPID1 316 26/128 20.3 41/188 21.8 0.78 2/128 1.6 4/188 2.1 1.0 
RAPID2 129 4/29 13.8 17/100 17.0 0.78 0/29 0 1/100 1.0 1.0 
LITHE 313 18/92 19.6 41/221 18.6 0.87 1/92 1.1 2/221 0.9 1.0 
DE013 204 23/122 18.8 26/82 31.7 0.04 3/122 2.5 5/82 6.1 0.27 
FUNCTION 457 11/179 6.1 27/278 9.7 0.22 0/179 0 0/278 0 na 
Pooled prevalence 
(95%CI) 
15.2%  
(9.9 to 21.4) 
18.4%  
(13.8 to 23.5) 
-- 
1.3%  
(0.6 to 2.3) 
2.3% 
(1.0 to 4.3%) 
-- 
1. Mean values at both 6 and 12 months. 
2. Using Fisher’s Exact test (2X2 contingency tables) 
NOTE: The % presented in the grey columns complement with the percentage of patients who did not progress in the 
same sub-group of PGA values. For instance, for the DE019 trial: 13 out of the 43 (30.2%) who had a PGA≤1 presented 
a damage progression >0.5 units and, thus, the remaining 30 patients (69.8%) presented a damage progression ≤0.5. 
 
 
 
 
 
 
 
